By analyzing the clinical data of 30 patients with BRCA wild‐type recurrence, multivariate Cox regression analysis showed that platinum‐based chemotherapy remained the key factor for prolonging TTSP (Figure 5D ), whereas a PARPi duration longer than 12 months again showed a trend towards a shorter TTSP duration. 4 Discussion The approval of olaparib for patients with BRCA‐mutated advanced OC has catalyzed the rapid development of PARPis and the expansion of their indications.
← all excerpts
Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study.
1
—
—